Massachusetts Medicaid

Does Massachusetts Medicaid cover Zepbound?

Find your Medicaid card name in Massachusetts

Quick answer · Weight Loss

Massachusetts Medicaid covers Zepbound for weight loss with prior authorization on Medicaid.

  • Medicaid: Covered with requirements. BMI of 35 or higher

Last verified June 4, 2026. Policy effective January 1, 2024. Source: Pa policy. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What Massachusetts Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 35 or higher
  • BMI of 27 or higher with a weight-related condition (heart failure with preserved ejection fraction, uncontrolled hypertension, CKD stage 3a or above, OSA, pre-diabetes, MI, stroke, MASH with moderate to advanced liver fibrosis, symptomatic peripheral artery disease, and T2DM)

Qualification pathways

You can qualify through any one of these.

Adult (>= 18 years): BMI >= 35 kg/m2 (no comorbidity required)

All of:

  • Appropriate diagnosis
  • Member is >= 18 years of age
  • Member weight documented within 90 days prior to initiation of pharmacotherapy for obesity
  • Member has been counseled to continue reduced-calorie diet and increased physical activity
  • Requested quantity <= 4 pens/28 days
  • Requested agent will not be used in combination with another GLP-1 receptor agonist
  • Member BMI is >= 35 kg/m2 (within 90 days prior to initiation)

Adult (>= 18 years): BMI >= 30 kg/m2 with specific high-severity comorbidity

All of:

  • Appropriate diagnosis
  • Member is >= 18 years of age
  • Member weight documented within 90 days prior to initiation of pharmacotherapy for obesity
  • Member has been counseled to continue reduced-calorie diet and increased physical activity
  • Requested quantity <= 4 pens/28 days
  • Requested agent will not be used in combination with another GLP-1 receptor agonist
  • Member BMI is >= 30 kg/m2 (within 90 days prior to initiation)

Plus any one of:

  • Heart failure with preserved ejection fraction
  • Uncontrolled hypertension (systolic BP > 140 mmHg or diastolic BP > 90 mmHg despite concurrent treatment with two antihypertensive medications)
  • Chronic kidney disease stage 3a or above
  • Moderate or severe obstructive sleep apnea (AHI > 15 without central or mixed sleep apnea)

Adult (>= 18 years): BMI >= 27 kg/m2 with qualifying comorbidity

All of:

  • Appropriate diagnosis
  • Member is >= 18 years of age
  • Member weight documented within 90 days prior to initiation of pharmacotherapy for obesity
  • Member has been counseled to continue reduced-calorie diet and increased physical activity
  • Requested quantity <= 4 pens/28 days
  • Requested agent will not be used in combination with another GLP-1 receptor agonist
  • Member BMI is >= 27 kg/m2 (within 90 days prior to initiation)

Plus any one of:

  • Pre-diabetes (A1c >= 5.7% and < 6.5%) and member is not a candidate for an anti-diabetic GLP-1 agent
  • History of myocardial infarction
  • History of stroke
  • Noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3)
  • Symptomatic peripheral artery disease
  • Type 2 diabetes mellitus

Documentation to bring

  • Documentation of appropriate diagnosis
  • Documentation that member is >= 18 years of age
  • Member weight dated within 90 days prior to initiation of pharmacotherapy for obesity
  • BMI documentation: >= 35 kg/m2 (no comorbidity); >= 30 kg/m2 with high-severity comorbidity; or >= 27 kg/m2 with qualifying comorbidity
  • Documentation of qualifying weight-related comorbid condition where applicable
  • Documentation that member has been counseled to continue reduced-calorie diet and increased physical activity
  • Attestation that requested agent will not be used in combination with another GLP-1 receptor agonist
  • Requested quantity <= 4 pens/28 days
  • For recertification: member weight within last 90 days AND one of: weight loss >= 5% from baseline, improvement in secondary measures with attestation, OSA symptom improvement with records verifying AHI >= 15, or CV risk reduction documentation with qualifying event

Quantity limits

  • all strengths — 4 pens per 28 days

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight and Weight loss >= 5% from baseline body weight; OR improvement in secondary measures with attestation that improvement is related to anti-obesity therapy; OR improvement in OSA symptoms (less daytime sleepiness, fewer sleep arousals, fewer partner-reported snoring/pauses) with attestation related to anti-obesity therapy and medical records verifying baseline or current OSA diagnosis with AHI >= 15; OR member requires a GLP-1 agent for cardiovascular risk reduction and benefit outweighs risk, with documented history of MI, ischemic or hemorrhagic stroke, or symptomatic PAD (intermittent claudication with ABI <0.85, peripheral arterial revascularization, or amputation due to atherosclerotic disease). Effective February 17, 2026, comorbid conditions and baseline BMI (prior to starting GLP-1) are used to determine continued eligibility; some members may no longer qualify at recertification. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Combination use with another GLP-1 receptor agonist is not permitted (GLP-1/GIP polypharmacy requires separate PA and transitioning off prior agent)
  • No pediatric coverage defined for Zepbound in this policy (adults >= 18 only)
  • For pre-diabetes comorbidity pathway: member must not be a candidate for an anti-diabetic GLP-1 agent

Policy note: MassHealth (Massachusetts Medicaid) policy. Zepbound requires PA. Listed as 'tirzepatide-Zepbound' in the drug table. Policy criteria for Zepbound (obesity/overweight) are parallel to Wegovy adult criteria but with no tablet formulation and no pediatric indication covered. Pre-diabetes defined as A1c >= 5.7% and < 6.5%. OSA (moderate/severe) defined as AHI > 15 without central or mixed sleep apnea. Uncontrolled hypertension defined as systolic BP > 140 mmHg or diastolic BP > 90 mmHg despite concurrent treatment with two antihypertensive medications. Recertification OSA pathway requires medical records verifying baseline OR current OSA diagnosis with AHI >= 15. Recertification CV pathway requires documented MI, ischemic or hemorrhagic stroke, or symptomatic PAD. Effective February 17, 2026, comorbid conditions and baseline BMI (prior to starting GLP-1) are used to determine continued eligibility. MassHealth pharmacy claims history may be used to evaluate adherence. Last revised 05/2026; page last updated 05/13/26.

Policy effective January 1, 2024 · verified June 4, 2026 · source: Pa policy

Why Zepbound requests get denied by Massachusetts Medicaid

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does Massachusetts Medicaid cover Zepbound?
Massachusetts Medicaid covers Zepbound for weight loss with prior authorization on Medicaid.
What BMI do you need for Zepbound under Massachusetts Medicaid?
For weight loss on Medicaid plans, Massachusetts Medicaid requires a BMI of 35 or higher, or 27 or higher with a qualifying weight-related condition.
What does Massachusetts Medicaid require to renew Zepbound?
At least 5% weight loss from the starting weight and Weight loss >= 5% from baseline body weight; OR improvement in secondary measures with attestation that improvement is related to anti-obesity therapy; OR improvement in OSA symptoms (less daytime sleepiness, fewer sleep arousals, fewer partner-reported snoring/pauses) with attestation related to anti-obesity therapy and medical records verifying baseline or current OSA diagnosis with AHI >= 15; OR member requires a GLP-1 agent for cardiovascular risk reduction and benefit outweighs risk, with documented history of MI, ischemic or hemorrhagic stroke, or symptomatic PAD (intermittent claudication with ABI <0.85, peripheral arterial revascularization, or amputation due to atherosclerotic disease). Effective February 17, 2026, comorbid conditions and baseline BMI (prior to starting GLP-1) are used to determine continued eligibility; some members may no longer qualify at recertification.
How current is this information?
This page reflects Massachusetts Medicaid's written policy as of January 1, 2024, last verified against the source document on June 4, 2026.

Other medications under Massachusetts Medicaid

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes Massachusetts Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.